{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:59:42Z","timestamp":1761663582243,"version":"build-2065373602"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,5]]},"abstract":"\n Study Objectives<\/jats:title>\n To evaluate the use of fosfomycin (FOS) at the single\u2010dose regimen approved by the U.S. Food and Drug Administration as well as off\u2010label multidose regimens for the treatment of cystitis after abdominal solid organ transplant (aSOT).<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Retrospective study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Tertiary academic medical center.<\/jats:p>\n <\/jats:sec>\n \n Patients<\/jats:title>\n Adult inpatients with history of aSOT receiving FOS between January 1, 2009, and April 30, 2015, for the treatment of cystitis.<\/jats:p>\n <\/jats:sec>\n \n Measurements and Main Results<\/jats:title>\n Seventy\u2010six courses of FOS were identified in 64 patients. Overall treatment success was 85.5%, with 11 failed treatment courses. Enterococcus was isolated in 59.3% of courses, of which 72.2% were vancomycin\u2010resistant enterococci (VRE). Gram\u2010negative organisms comprised a quarter of isolated bacteria, with most resistant to three or more antimicrobial classes. In the 11 failed treatment courses, 90% were targeted against enterococcus, of which 82% were VRE. Six of these failures (54%) were successfully retreated with uroselective therapy (FOS or nitrofurantoin). No significant difference in the success rate of single\u2010dose versus multidose therapy was seen (80.6% vs 90%, p=0.33). Concomitant systemic antibiotics for other indications\u00a0were present in 36.8% of courses, and they were significantly more frequent in the multidose group (67.5% vs 47.2%, p=0.04). However, multivariable logistic regression analysis found that after adjustment for broad\u2010spectrum antibiotic use, no statistically significant difference in failure rates was found between the two regimens (p=0.42).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n FOS appears to be successful in the treatment of cystitis in aSOT recipients. Multidose therapy did not significantly improve success over a single\u2010dose regimen. Further prospective studies are needed to elucidate the true efficacy of FOS in the aSOT population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/phar.1924","type":"journal-article","created":{"date-parts":[[2017,3,12]],"date-time":"2017-03-12T06:53:00Z","timestamp":1489301580000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population"],"prefix":"10.1002","volume":"37","author":[{"given":"Ashley A.","family":"Loethen","sequence":"first","affiliation":[{"name":"University of Wisconsin\u2010Madison School of Pharmacy Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiza","family":"Kerstenetzky","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian L.","family":"Descourouez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen E.","family":"Leverson","sequence":"additional","affiliation":[{"name":"Department of Surgery University of Wisconsin\u2010Madison School of Medicine and Public Health Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannina A.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin\u2010Madison School of Medicine and Public Health Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret R.","family":"Jorgenson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy University of Wisconsin Hospital and Clinics Madison Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.10.059"},{"key":"e_1_2_5_3_1","unstructured":"Zambon Switzerland Ltd. Monurol (fosfomycin) package insert. Cadempino Switzerland2011."},{"key":"e_1_2_5_4_1","first-page":"1128","article-title":"Experience with fosfomycin for the treatment of urinary tract infections due to multi\u2010drug resistant organisms","volume":"10","author":"Neuner EA","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.039"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.06.061"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318298dd26"},{"issue":"5","key":"e_1_2_5_8_1","article-title":"Oral Treatment of Multi\u2010Drug Resistant Urinary Tract Infection in Transplant Recipients: Resurgence of Fosfomycin [abstract]","volume":"13","author":"Noell B","year":"2013","journal-title":"Am J Transplant"},{"issue":"3","key":"e_1_2_5_9_1","article-title":"Prophylaxis of post\u2010renal transplant urinary tract infection with fosfomycin trometamol. A controlled, randomized clinical trial (intermediate analysis) [abstract]","volume":"15","author":"Arreola\u2010Guerra J","year":"2015","journal-title":"Am J Transplant"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/321815"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02099-12"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.07.012"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.4065\/81.9.1159"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:44:24Z","timestamp":1761068664000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1002\/phar.1924"],"URL":"https:\/\/doi.org\/10.1002\/phar.1924","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2017,4,17]]},"assertion":[{"value":"2017-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}